Ítems similars: Aliskirin Case Study: Will Aliskiren Live Up to the Hype & Achieve Blockbuster Status?
- Pfizer Case Study: Protecting Blockbuster Drugs from Generic Competition
- Prevnar: the First Vaccine Blockbuster
- GlaxoSmithKline Case Study: Switching Drugs to OTC Status Effectively
- Johnson & Johnson Case Study: Remicade, a Biotech Blockbuster
- Lipitor Case Study: Lifecycle Management Strategies
- Improving Growth & Profits: Roche Pharmaceuticals Case Study